These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

805 related items for PubMed ID: 33909949

  • 1. Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration.
    Ravi P, Pond GR, Diamantopoulos LN, Su C, Alva A, Jain RK, Skelton WP, Gupta S, Tward JD, Olson KM, Singh P, Grunewald CM, Niegisch G, Lee JL, Gallina A, Bandini M, Necchi A, Mossanen M, McGregor BA, Curran C, Grivas P, Sonpavde GP.
    BJU Int; 2021 Nov; 128(5):607-614. PubMed ID: 33909949
    [Abstract] [Full Text] [Related]

  • 2. Effectiveness of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin as compared to gemcitabine-based regimens as neoadjuvant chemotherapy for oncologic outcomes in muscle-invasive bladder cancer cases-Single-center study in Japan.
    Mitsui Y, Okawa M, Hori S, Uetani M, Kasahara M, Yamabe F, Kobayashi H, Nagao K, Nakajima K.
    Int J Urol; 2024 Sep; 31(9):1030-1037. PubMed ID: 38819073
    [Abstract] [Full Text] [Related]

  • 3. Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy.
    Zargar H, Shah JB, van Rhijn BW, Daneshmand S, Bivalacqua TJ, Spiess PE, Black PC, Kassouf W, Collaborators.
    J Urol; 2018 Jun; 199(6):1452-1458. PubMed ID: 29329894
    [Abstract] [Full Text] [Related]

  • 4. Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses.
    Pfister C, Gravis G, Fléchon A, Soulié M, Guy L, Laguerre B, Mottet N, Joly F, Allory Y, Harter V, Culine S, VESPER Trial Investigators.
    Eur Urol; 2021 Feb; 79(2):214-221. PubMed ID: 32868138
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients.
    Hamid ARAH, Ridwan FR, Parikesit D, Widia F, Mochtar CA, Umbas R.
    BMC Urol; 2020 Oct 14; 20(1):158. PubMed ID: 33054762
    [Abstract] [Full Text] [Related]

  • 8. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer.
    Zargar H, Espiritu PN, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Gandhi NM, Griffin J, Montgomery JS, Vasdev N, Yu EY, Youssef D, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, Sridhar SS, McGrath JS, Aning J, Shariat SF, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Garcia JA, Stephenson AJ, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Black PC.
    Eur Urol; 2015 Feb 14; 67(2):241-9. PubMed ID: 25257030
    [Abstract] [Full Text] [Related]

  • 9. Relative efficacy of perioperative gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management of locally advanced urothelial carcinoma of the bladder.
    Yeshchina O, Badalato GM, Wosnitzer MS, Hruby G, RoyChoudhury A, Benson MC, Petrylak DP, McKiernan JM.
    Urology; 2012 Feb 14; 79(2):384-90. PubMed ID: 22196406
    [Abstract] [Full Text] [Related]

  • 10. Phase II study of neoadjuvant chemotherapy with four cycles of dose-dense MVAC followed by radical cystectomy in Korean patients with muscle-invasive or locally advanced urothelial carcinoma of bladder.
    Park K, Lee HJ, Kim TU, Ryu H, Ki YK, Hong YJ, Nam JK.
    Asia Pac J Clin Oncol; 2023 Dec 14; 19(6):739-746. PubMed ID: 37461246
    [Abstract] [Full Text] [Related]

  • 11. Cigarette smoking is associated with adverse pathological response and increased disease recurrence amongst patients with muscle-invasive bladder cancer treated with cisplatin-based neoadjuvant chemotherapy and radical cystectomy: a single-centre experience.
    Boeri L, Soligo M, Frank I, Boorjian SA, Thompson RH, Tollefson M, Quevedo FJ, Cheville JC, Karnes RJ.
    BJU Int; 2019 Jun 14; 123(6):1011-1019. PubMed ID: 30623554
    [Abstract] [Full Text] [Related]

  • 12. Comparison of clinical outcomes in patients with localized or locally advanced urothelial carcinoma treated with neoadjuvant chemotherapy involving gemcitabine-cisplatin and high dose-intensity MVAC.
    Lee Y, Kim YS, Hong B, Cho YM, Lee JL.
    J Cancer Res Clin Oncol; 2021 Nov 14; 147(11):3421-3429. PubMed ID: 33715088
    [Abstract] [Full Text] [Related]

  • 13. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer.
    Galsky MD, Pal SK, Chowdhury S, Harshman LC, Crabb SJ, Wong YN, Yu EY, Powles T, Moshier EL, Ladoire S, Hussain SA, Agarwal N, Vaishampayan UN, Recine F, Berthold D, Necchi A, Theodore C, Milowsky MI, Bellmunt J, Rosenberg JE, Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators.
    Cancer; 2015 Aug 01; 121(15):2586-93. PubMed ID: 25872978
    [Abstract] [Full Text] [Related]

  • 14. Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: Japan Clinical Oncology Group Study JCOG0209.
    Kitamura H, Tsukamoto T, Shibata T, Masumori N, Fujimoto H, Hirao Y, Fujimoto K, Kitamura Y, Tomita Y, Tobisu K, Niwakawa M, Naito S, Eto M, Kakehi Y, Urologic Oncology Study Group of the Japan Clinical Oncology Group.
    Ann Oncol; 2014 Jun 01; 25(6):1192-8. PubMed ID: 24669010
    [Abstract] [Full Text] [Related]

  • 15. Neoadjuvant Cisplatin-based Chemotherapy in Nonmetastatic Muscle-invasive Bladder Cancer: A Systematic Review and Pooled Meta-analysis to Determine the Preferred Regimen.
    Eule CJ, Warren A, Molina Kuna E, Callihan EB, Kim SP, Flaig TW.
    Urology; 2024 Jun 01; 188():118-124. PubMed ID: 38685388
    [Abstract] [Full Text] [Related]

  • 16. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates.
    Choueiri TK, Jacobus S, Bellmunt J, Qu A, Appleman LJ, Tretter C, Bubley GJ, Stack EC, Signoretti S, Walsh M, Steele G, Hirsch M, Sweeney CJ, Taplin ME, Kibel AS, Krajewski KM, Kantoff PW, Ross RW, Rosenberg JE.
    J Clin Oncol; 2014 Jun 20; 32(18):1889-94. PubMed ID: 24821883
    [Abstract] [Full Text] [Related]

  • 17. Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder: a contemporary series.
    Weight CJ, Garcia JA, Hansel DE, Fergany AF, Campbell SC, Gong MC, Jones JS, Klein EA, Dreicer R, Stephenson AJ.
    Cancer; 2009 Feb 15; 115(4):792-9. PubMed ID: 19127557
    [Abstract] [Full Text] [Related]

  • 18. Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: efficacy and safety compared with classic MVAC and gemcitabine/cisplatin.
    van de Putte EE, Mertens LS, Meijer RP, van der Heijden MS, Bex A, van der Poel HG, Kerst JM, Bergman AM, Horenblas S, van Rhijn BW.
    World J Urol; 2016 Feb 15; 34(2):157-62. PubMed ID: 26184106
    [Abstract] [Full Text] [Related]

  • 19. Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
    Pfister C, Gravis G, Flechon A, Chevreau C, Mahammedi H, Laguerre B, Guillot A, Joly F, Soulie M, Allory Y, Harter V, Culine S, VESPER Trial Investigators.
    Lancet Oncol; 2024 Feb 15; 25(2):255-264. PubMed ID: 38142702
    [Abstract] [Full Text] [Related]

  • 20. Retrospective analysis of clinical outcomes with neoadjuvant cisplatin-based regimens for muscle-invasive bladder cancer.
    Pal SK, Ruel NH, Wilson TG, Yuh BE.
    Clin Genitourin Cancer; 2012 Dec 15; 10(4):246-50. PubMed ID: 22981208
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.